GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo

Pozen is counting on safety data from two GSK Phase IIIb trials completed after the migraine therapy’s filing to satisfy FDA’s “approvable” letter.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet